glyburide has been researched along with pioglitazone in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.15) | 18.2507 |
| 2000's | 29 (44.62) | 29.6817 |
| 2010's | 24 (36.92) | 24.3611 |
| 2020's | 8 (12.31) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Darvesh, AS; Geldenhuys, WJ; Leeper, TC; Morris, DL; Sullivan, PG; Yonutas, HM | 1 |
| Ahn, S; An, S; Choi, JM; Choi, MS; Kwon, SW; Le, THV; Lee, J; Lee, M; Ma, CT; Noh, M; Park, JH; Pyo, JJ | 1 |
| Norman, BH | 1 |
| An, S; Choi, H; Hyun, YE; Jeong, LS; Kim, G; Kim, JA; Nguyen, M; Nguyen, Y; Noh, M; Pham, L | 1 |
| An, S; Deyrup, ST; Hur, JS; Kim, J; Ko, H; Lee, JW; Noh, M; Shim, SH | 1 |
| Hodorek, MJ; Iannucci, AR; Peuler, JD; Phare, SM | 1 |
| Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS | 1 |
| Bourghli, M; Miller, JA; Peuler, JD; Soltis, EE; Sowers, JR; Zammam, HY | 1 |
| Gonoi, T; Inagaki, N; Ishida, H; Seino, S; Seino, Y; Sunaga, Y; Yamada, Y | 1 |
| Ebeling, P; Koistinen, HA; Koivisto, VA; Teppo, AM | 1 |
| Ebihara, I; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Abe, T; Ishibashi, S; Ishikawa, S; Kawakami, A; Kusaka, I; Nagasaka, S; Nakamura, T; Saito, T | 1 |
| Braddon, J; Phillips, P | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Chandalia, HB; Fafadia, A; Joshi, SR; Panikar, V; Santvana, C | 1 |
| Clausen, J; Eriksson, JW; Halse, J; Herz, M; Johns, D; Konkoy, CS; Madsbad, S; Strand, J; Tan, MH | 1 |
| Croom, DK; Lenhard, JM; Minnick, DT | 1 |
| Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I | 1 |
| Chow, CC; Filipczak, R; Joshi, P; Lertoft, B; Rastam, J; Raz, I; Shaban, J; Stranks, S | 1 |
| Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P | 1 |
| Itoh, Y; Mori, Y; Obata, T; Tajima, N | 1 |
| Costa, DB; Huberman, MS | 1 |
| Forst, T; Hanefeld, M; Lübben, G; Pfützner, A | 1 |
| Hara, M; Nakagawa, M; Ooie, T; Saikawa, T; Shinohara, T; Takahashi, N; Taniguchi, Y; Yonemochi, H; Yoshimatsu, H | 1 |
| Dorkhan, M; Frid, A; Groop, L; Grubb, A; Jovinge, S; Magnusson, M | 1 |
| Jain, R; Kupfer, S; Osei, K; Perez, AT; Zhang, J | 1 |
| Ari, N; Aslamaci, S; Irat, AM; Karasu, C | 1 |
| Ebeling, P; Heliövaara, MK; Herz, M; Leinonen, E; Teppo, AM | 1 |
| Willeke, A | 1 |
| Bellatreccia, A; Comaschi, M; Demicheli, A; Di Pietro, C; Mariz, S | 1 |
| Bellatreccia, A; Comaschi, M; Corsi, A; Di Pietro, C; Mariz, S | 1 |
| Al Majali, K; Bailey, CJ; Betteridge, DJ; Cooper, MB | 1 |
| Balez, S; Bullock, J; Dole, WP; He, YL; Jarugula, V; Ligueros-Saylan, M; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Birnbaum, Y; Lin, Y; Perez-Polo, JR; Ye, Y | 1 |
| Aso, Y; Hara, K; Haruki, K; Inukai, T; Matsumoto, S; Nakamachi, T; Nakano, T; Ozeki, N; Suetsugu, M; Takebayashi, K; Yatsuka, C | 1 |
| Adams-Huet, B; Kaloyanova, PF; Legendre, JL; Lingvay, I; Raskin, P; Zhang, S | 1 |
| Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E | 1 |
| Freston, JW; Kupfer, S; Perez, A; Tolman, KG | 1 |
| Abdul-Razzak, KK; Al-Azzam, SI; Jaradat, MW | 1 |
| Baraka, A; ElGhotny, S | 1 |
| Arayne, MS; Mirza, AZ; Sultana, N | 1 |
| Boulton, DW; Brenner, E; Handschuh del Corral, M; Komoroski, B; Kornhauser, D; Li, L; Patel, CG; Vachharajani, N | 1 |
| Bianchi, L; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P | 1 |
| Scheen, AJ | 1 |
| Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S | 1 |
| Alonso, E; Aparicio, I; Buchberger, W; Martín, J; Santos, JL | 1 |
| Adams-Huet, B; Harrison, LB; Lingvay, I; Raskin, P | 1 |
| Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS | 1 |
| Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
| D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T | 1 |
| AbuKhader, MM; Alqtaishat, S; Khanfar, MA; Taha, MO | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Bombicz, M; Hegedűs, C; Juhász, B; Kiss, R; Kovács, D; Németh, J; Priksz, D; Szabó, AM; Szilvássy, Z; Varga, B; Wachal, Z | 1 |
| Cheng, PW; Lin, HL; Shen, KP; Tu, YC; Wu, BN; Yeh, BC | 1 |
| Aiceles de Medeiros Pinto, V; da Fonte Ramos, C; Devantier Neuenfeldt, P; Gonçalves Marques Elias, R; Mena Barreto Silva, FR; Nunes, RJ; Pires Mendes, C; Postal, BG; Silva Frederico, MJ | 1 |
| Cheng, PW; Hao, CL; Lin, HL; Shen, KP; Tu, YC; Wu, BN; Yeh, BC | 1 |
| Jannetto, PJ; Langman, LJ | 1 |
6 review(s) available for glyburide and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Glyburide; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2011 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
24 trial(s) available for glyburide and pioglitazone
| Article | Year |
|---|---|
Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes.
Topics: Acute-Phase Proteins; Blood Glucose; Blood Proteins; C-Reactive Protein; Complement Activation; Complement C3; Complement C3a; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osmolar Concentration; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Pioglitazone; Renal Dialysis; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2004 |
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide.
Topics: Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glyburide; Humans; Insulin Resistance; Male; Middle Aged; Pioglitazone; Pulse; Risk Factors; Thiazolidinediones; Time Factors; Triglycerides | 2005 |
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Thiazolidinediones; Time Factors; Triglycerides; Weight Gain | 2005 |
Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoprotein Lipase; Male; Middle Aged; Oxidative Stress; Pioglitazone; Postprandial Period; Thiazolidinediones; Time Factors; Triglycerides; Tyrosine | 2006 |
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Primary Health Care; Prospective Studies; Thiazolidinediones; Treatment Outcome | 2006 |
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.
Topics: Adiponectin; Administration, Oral; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pioglitazone; Proinsulin; Prospective Studies; Statistics, Nonparametric; Thiazolidinediones | 2006 |
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Assessment; Thiazolidinediones; Time Factors | 2006 |
Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Hemoglobins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Orosomucoid; Pioglitazone; Serum Amyloid A Protein; Thiazolidinediones | 2007 |
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Safety; Thiazolidinediones | 2007 |
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Topics: Aged; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Glyburide; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2008 |
Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Postprandial Period; Proinsulin; Thiazolidinediones | 2008 |
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pioglitazone; Pyrrolidines; Thiazolidinediones; Vildagliptin | 2008 |
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2009 |
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Approval; Endpoint Determination; Female; Glyburide; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Middle Aged; Pioglitazone; Thiazolidinediones; United States; United States Food and Drug Administration; Young Adult | 2009 |
Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Young Adult | 2011 |
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Topics: Administration, Oral; Biomarkers; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Lipids; Male; Pioglitazone; Thiazolidinediones | 2011 |
β-cell function preservation after 3.5 years of intensive diabetes therapy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Patient Compliance; Pioglitazone; Thiazolidinediones | 2012 |
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Triglycerides; Young Adult | 2012 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Fluorobenzenes; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Intra-Abdominal Fat; Italy; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography | 2013 |
35 other study(ies) available for glyburide and pioglitazone
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
Topics: Hypoglycemic Agents; Ligands; Mitochondrial Proteins; Protein Binding; Small Molecule Libraries; Thiazolidinediones | 2016 |
Adiponectin-Secretion-Promoting Phenylethylchromones from the Agarwood of Aquilaria malaccensis.
Topics: Adiponectin; Cells, Cultured; Chromones; Humans; PPAR gamma; Thymelaeaceae; Wood | 2019 |
Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
Topics: | 2022 |
Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus,
Topics: Adiponectin; Ascomycota; Humans; Naphthols; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma | 2022 |
Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation.
Topics: Animals; Aorta, Thoracic; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1996 |
Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice.
Topics: Animals; Blood Glucose; Body Weight; Carcinoma, Hepatocellular; Cell Division; Diabetes Mellitus, Type 2; DNA; Dose-Response Relationship, Drug; Drug Synergism; Glyburide; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured | 1997 |
Disparate effects of antidiabetic drugs on arterial contraction.
Topics: Animals; Arteries; Blood Pressure; Glyburide; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Male; Metformin; Muscle Contraction; Muscle, Smooth, Vascular; Pioglitazone; Potassium Chloride; Rats; Rats, Wistar; Tail; Thiazoles; Thiazolidinediones | 1997 |
Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Chromans; COS Cells; Diazoxide; Electrophysiology; Glyburide; Membrane Potentials; Pinacidil; Pioglitazone; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Recombinant Fusion Proteins; Rubidium Radioisotopes; Sulfonylurea Receptors; Thiazoles; Thiazolidinediones; Transfection; Troglitazone | 1999 |
Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2003 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Hemoglobins; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metformin; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Precursors; Rats; Rats, Zucker; Thiazolidinediones | 2004 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2006 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 2; Fever; Glucose Tolerance Test; Glyburide; HSP72 Heat-Shock Proteins; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred OLETF; Thiazolidinediones; Ventricular Function, Left | 2006 |
Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones.
Topics: Aged; Cromakalim; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Mammary Arteries; Middle Aged; Nitroprusside; Phenylephrine; Pioglitazone; Potassium Channel Blockers; Potassium Chloride; Rosiglitazone; Thiazolidinediones; Vasoconstriction | 2006 |
[Status of glitazones in treatment of type 2 diabetes mellitus].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Management; Drug Costs; Drug Therapy, Combination; Germany; Glyburide; Humans; Hypoglycemic Agents; Long-Term Care; Metformin; Pioglitazone; Practice Guidelines as Topic; Survival Analysis; Thiazolidinediones | 2007 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Decanoic Acids; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glyburide; Hydroxy Acids; Injections, Intravenous; Intubation, Gastrointestinal; KATP Channels; Ligation; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Pioglitazone; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Thiazolidinediones; Ventricular Remodeling | 2008 |
Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Patient Selection; Pioglitazone; Sex Characteristics; Thiazolidinediones | 2009 |
The nephroprotective effects of pioglitazone and glibenclamide against gentamicin-induced nephrotoxicity in rats: a comparative study.
Topics: Animals; Antioxidants; Creatinine; Disease Models, Animal; Gentamicins; Glyburide; Kidney Diseases; Lipid Peroxidation; Male; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rats; Rats, Wistar; Thiazolidinediones | 2010 |
Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Brain; Cognition Disorders; Disease Models, Animal; Drug Administration Schedule; Galanin; Glyburide; Hippocampus; Hypoglycemic Agents; Learning; Male; Memory; Pioglitazone; Rats; Rats, Wistar; tau Proteins; Thiazolidinediones | 2010 |
Simultaneous determination of gliquidone, pioglitazone hydrochloride, and verapamil in formulation and human serum by RP-HPLC.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Glyburide; Humans; Linear Models; Pioglitazone; Reproducibility of Results; Sensitivity and Specificity; Sulfonylurea Compounds; Tablets; Thiazolidinediones; Verapamil | 2011 |
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; Glyburide; Hydroxy Acids; Hypoglycemic Agents; Ischemia; Ischemic Preconditioning, Myocardial; Male; Pioglitazone; Potassium Channel Blockers; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation | 2012 |
High-performance liquid chromatography quadrupole time-of-flight mass spectrometry method for the analysis of antidiabetic drugs in aqueous environmental samples.
Topics: Chromatography, High Pressure Liquid; Drinking Water; Glyburide; Hydrogen-Ion Concentration; Hypoglycemic Agents; Mass Spectrometry; Metformin; Pioglitazone; Reproducibility of Results; Rivers; Sensitivity and Specificity; Sodium Dodecyl Sulfate; Solid Phase Extraction; Thiazolidinediones; Water Pollutants, Chemical | 2012 |
Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone.
Topics: Adrenergic beta-Antagonists; Amino Acid Sequence; Anti-Infective Agents; Catalytic Domain; Crystallography, X-Ray; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metipranolol; Models, Molecular; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Pioglitazone; Quantitative Structure-Activity Relationship; ROC Curve; Sequence Alignment; Sotalol; Sulfamethizole; Thiazolidinediones; TOR Serine-Threonine Kinases | 2013 |
Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Electroretinography; Glyburide; Humans; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Male; Metformin; Molecular Structure; Oximes; Pioglitazone; Piperidines; Protective Agents; Rats; Rats, Wistar; Retina | 2020 |
The effectiveness comparisons of eugenosedin-A, glibenclamide and pioglitazone on diabetes mellitus induced by STZ/NA and high-fat diet in SHR.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Glyburide; Hypertension; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Piperazines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Streptozocin | 2021 |
Synthesis of a novel glibenclamide-pioglitazone hybrid compound and its effects on glucose homeostasis in normal and insulin-resistant rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glyburide; Homeostasis; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Molecular Structure; Pioglitazone; Rats; Structure-Activity Relationship | 2021 |
Efficiency comparison of an isoeugenol-derivated compound, eugenosedin-A, with glibenclamide and pioglitazone in protecting cardiovascular dysfunction of diabetic SHR.
Topics: Animals; Diabetes Mellitus, Experimental; Glyburide; Hypoglycemic Agents; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley | 2023 |
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide | 2024 |